Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
Adverse events will be closely watched when full data are reported.
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
The Avanzar study could read out shortly.
The company reckons its immunotherapy could improve on Keytruda.
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
Satri-cel is filed for gastric cancer approval in China.
